Treatment options in patients with metastatic gastric cancer: Current status and future perspectives

Table 1 Selected phase III clinical trials of current chemotherapy regimens for patients with advanced gastric cancer in the first-line setting

Ref.	Regimen	No. of patients	Response rate	Median PFS/TTP and OS (mo)
Van Cutsem et al[23]	DCF vs CF	445	37% vs 25%	TTP, 5.6 vs 3.7; OS, 9.2 vs 8.6
Cunningham et al[20]	EOF vs EOX vs ECX vs ECF	1002	42.4% vs 47.9% vs 46.4% vs 40.7%	PFS, 6.5 vs 7.0 vs 6.7 vs 6.2;OS, 9.3 vs 11.2 vs 9.9 vs 9.9
Kang et al[21]	CX vs CF	316	41% vs 29%	PFS, 5.6 vs 5.0; OS, 10.5 vs 9.3
Al-Batran et al[24]	FLC vs FLO	220	34.8% vs 24.5%	PFS, 5.8 vs 3.9; OS, 10.7 vs 8.8
Dank et al[32]	IF vs CF	333	31.8% vs 25.8%	TTP, 5.0 vs 4.2; OS, 9.0 vs 8.7
Koizumi et al[36]	CS vs S	305	54% vs 31%	PFS, 6.0 vs 4.0; OS, 13 vs 11
Ajani et al[39]	CS vs CF	1053	29.1% vs 31.9%	PFS, 4.8 vs 5.5; OS, 8.6 vs 7.9
Yoshida et al[40]	DS vs S	635	38.8% vs 26.8%	PFS, 5.29 vs 4.17; OS, 12.48 vs 10.78

DCF: Docetaxel, cisplatin and fluorouracil; CF: Cisplatin and fluorouracil; EOF: Epirubicin, oxaliplatin and fluorouracil; EOX: Epirubicin, oxaliplatin and capecitabine; ECX: Epirubicin, cisplatin and capecitabine; ECF: Epirubicin, cisplatin and fluorouracil; CX: Cisplatin and capecitabine; FLO: Fluorouracil, leucovorin and oxaliplatin; FLC: Fluorouracil, leucovorin and cisplatin; IF: Irinotecan and cisplatin; CS: Cisplatin and S-1; S: S-1; DS: Docetaxel and S-1; PFS: Progression-free survival; OS: Overall survival; TTP: Time-to progression.